Progress in Treatment of Advanced Non-Hodgkin’s Lymphoma in Children — Report on Behalf of the Polish Children’s Leukemia/Lymphoma Study Group

Bogusławska-Jaworska, J; Rodziewicz, B; Kazanowska, Bernarda; Armata, J; Cyklis, R; Daszkiewicz, Paweł; Dłużniewska, Agnieszka; Matysiak, Michał; Ochocka, M; Radwańska, U; Rokicka-Milewska, R; Sroczyńska, M; Wójcik, Z; Zmudzka, I

doi:10.1007/978-3-642-72624-8_9

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Children admitted from January 1983 to July 1986 (second period) were treated according to the preceding protocol modified by the addition of intermediate-dose MTX (LSA2-L2-MTX) during the induction phase. 4 The systemic MTX was delivered as two different schemes assigned to nonconcurrent study arms during the second period. The first 28 children entering the LSA2-L2-MTX phase received 300 mg/m2 of the drug partitioned between a single-push injection for 60% of the dose and a 4-hour continuous infusion for the remaining 40% of the agent.…”

Section: Completion Of the Consolidation Phase Wasmentioning

confidence: 99%

Factors of prognostic importance in childhood non-hodgkin's lymphoma treated with two modified lsa2-l2 protocols. A multivariate analysis approach

Andrea

Franco

Alves

et al. 1988

Cancer

View full text Add to dashboard Cite

The results of therapy given to 74 children with advanced disease, abdominal non-Hodgkin's lymphoma were retrospectively evaluated with respect to the major prognostic factors related to disease outcome. The first 36 patients admitted in the study were treated with a modified LSA2-L2 protocol, and the remaining patients received the same regimen with the addition of intermediate-dose methotrexate (MTX) intravenously during the induction phase (LSA2-L2-MTX). The last ten patients admitted were given a leucovorin rescue along with the administration of MTX. The relative efficacy of the LSA2-L2-MTX over the baseline LSA2-L2 regimen was analyzed by multivariate statistical methods taking into consideration several candidate coprognostic factors. The risk of treatment failure was substantially reduced (55%) with the use of the LSA2-L2-MTX regimen. Rescue with leucovorin did not contribute a further significant gain in treatment efficacy, although fewer toxicity-related problems were observed as compared to the no-rescue period. Five prognostic factors emerged as significantly explanatory of the risk of treatment failure in addition to protocol type: lymphocyte count, disease stage, surgical debulking, sex, and nutritional status. Based on these variables, a logistic regression equation could be derived to identify groups that were at risk for treatment failure.

show abstract

Section: Completion Of the Consolidation Phase Wasmentioning

confidence: 99%